Bio-Rad Laboratories Inc

Bio-Rad Laboratories reported second-quarter 2026 total net sales of approximately $651 million, essentially flat on a reported basis and down 1.9 percent on a currency-neutral basis. Clinical Diagnostics sales were approximately $399 million, an increase of 2.6 percent on a reported basis and 8.3 percent on a currency-neutral basis, led by quality systems, diabetes, and blood typing products. Life Science segment revenue was $252 million, a 5.1 percent currency-neutral decrease driven by academic research challenges and a difficult comparison in process chromatography. Digital PCR instrument revenue increased more than 20 percent, reflecting competitive wins and conversions from traditional qPCR platforms. Non-GAAP operating margin was 12.5 percent, a sequential improvement from 6.6 percent in the first quarter, and non-GAAP net income was $70.2 million, or $2.62 per diluted share. The company reaffirmed its full-year 2026 guidance for currency-neutral revenue growth between minus 3 percent and plus 0.5 percent and non-GAAP operating margin of 10 to 12 percent, while announcing a restructuring expected to yield $30 million to $35 million in annualized net savings by the end of 2027.

Simply Wall St has raised its fair value estimate for Biocon to ₹429.67 from ₹416.53, reflecting a shift in peer valuation cues and a greater emphasis on margin improvement plans. The updated model incorporates a lower revenue growth assumption of 14.01% and a reduced net profit margin of 10.73%, while the forward P/E multiple applied to projected earnings increased to 45.01 times from 35.56 times and the discount rate edged down to 13.21% from 13.45%. The revision follows recent analyst actions on peer Bio Rad, where RBC Capital, Citi, and Wells Fargo raised price targets, highlighting that the market is willing to assign higher multiples when there is visibility on execution, even in a tough macro environment. However, Wells Fargo's Equal Weight stance on Bio Rad underscores that execution risk and external headwinds may limit further valuation expansion for companies like Biocon.